A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Recruiting · NCT05735184 · Registry updated 2026-03-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, acute myeloid leukemia, acute myeloid leukemia with mutated NPM1, hematologic disorder, hematopoietic and lymphoid system neoplasm, leukemia, myeloid leukemia, myeloid sarcoma, neoplasm, sarcoma | Recruiting | Phase 1 | 2026-03-13 | NCT05735184 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Kura Oncology, Inc. | 11 |
44 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.